Federal Gov't Said to Claim Mylan (MYL) Overcharged Medicaid Over EpiPen
- Record-setting rally pushes on as S&P ends week up 3 percent
- Trump's Cohn Pick Most Bullish Sign Yet for Banks - Cowen
- Unusual 11 Mid-Day Movers: (IDXG) (INVN) (EBS) Higher; (SCON) (DTEA) (DLTH) Lower (more...)
- 21st Century Fox (FOXA) offers to acquire Sky for GBP10.75/share
- Coca Cola (KO) Announces James Quincey to Succeed Muhtar Kent as CEO; Kent to Continue as Chairman
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Mylan (Nasdaq: MYL) shares are on watch following news that the Federal government is accusing the company of overcharging the Medicaid program by millions of dollars for its EpiPen product.
The WSJ noted commentary from Acting Administrator Andy Slavitt of the federal Centers for Medicare and Medicaid Services (CMS) in a letter on Wednesday.
Slavitt said Mylan incorrectly classified EpiPen as generic, when it should have been classified as brand name. That allow Mylan to pay a rebate of just 13%, or around $163 million, versus a rebate of 23.1 percent or more than it should've been paying.
Slavitt noted that the CMS has,
on multiple occasions provided guidance to the industry and Mylan on the proper classification of drugs and has expressly told Mylan that the product is incorrectly classified.
Shares of Mylan are flat Thursday morning.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- VirnetX Holding (VHC) Disappointed on Federal Circuit's Decisions; Positive on Dissenter
- Whirlpool (WHR) Announces U.S. Confirms Samsung and LG Dumped Washers
- Volatility and Volume movement
Create E-mail Alert Related CategoriesLitigation, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!